Literature DB >> 20932672

Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer.

Nadine Housri1, Holly Ning, John Ondos, Peter Choyke, Kevin Camphausen, Deborah Citrin, Barbara Arora, Uma Shankavaram, Aradhana Kaushal.   

Abstract

PURPOSE: To identify , within the framework of a current Phase I trial, whether factors related to intraprostatic cancer lesions (IPLs) or individual patients predict the feasibility of high-dose intraprostatic irradiation. METHODS AND MATERIALS: Endorectal coil MRI scans of the prostate from 42 men were evaluated for dominant IPLs. The IPLs, prostate, and critical normal tissues were contoured. Intensity-modulated radiotherapy plans were generated with the goal of delivering 75.6 Gy in 1.8-Gy fractions to the prostate, with IPLs receiving a simultaneous integrated boost of 3.6 Gy per fraction to a total dose of 151.2 Gy, 200% of the prescribed dose and the highest dose cohort in our trial. Rectal and bladder dose constraints were consistent with those outlined in current Radiation Therapy Oncology Group protocols.
RESULTS: Dominant IPLs were identified in 24 patients (57.1%). Simultaneous integrated boosts (SIB) to 200% of the prescribed dose were achieved in 12 of the 24 patients without violating dose constraints. Both the distance between the IPL and rectum and the hip-to-hip patient width on planning CT scans were associated with the feasibility to plan an SIB (p = 0.002 and p = 0.0137, respectively).
CONCLUSIONS: On the basis of this small cohort, the distance between an intraprostatic lesion and the rectum most strongly predicted the ability to plan high-dose radiation to a dominant intraprostatic lesion. High-dose SIB planning seems possible for select intraprostatic lesions. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20932672      PMCID: PMC3580994          DOI: 10.1016/j.ijrobp.2010.06.050

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  36 in total

1.  Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy.

Authors:  P Xia; B Pickett; E Vigneault; L J Verhey; M Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

2.  Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.

Authors:  Jean Pouliot; Yongbok Kim; Etienne Lessard; I-Chow Hsu; Daniel B Vigneron; John Kurhanewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

3.  Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10).

Authors:  P A Kupelian; J C Buchsbaum; C A Reddy; E A Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

4.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

5.  Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study.

Authors:  V S Khoo; A R Padhani; S F Tanner; D J Finnigan; M O Leach; D P Dearnaley
Journal:  Br J Radiol       Date:  1999-06       Impact factor: 3.039

6.  Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.

Authors:  Eugene H Huang; Alan Pollack; Larry Levy; George Starkschall; Lei Dong; Isaac Rosen; Deborah A Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

7.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.

Authors:  Alan Pollack; Gunar K Zagars; George Starkschall; John A Antolak; J Jack Lee; Eugene Huang; Andrew C von Eschenbach; Deborah A Kuban; Isaac Rosen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

8.  Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Authors:  John J Coen; Anthony L Zietman; Harjot Thakral; William U Shipley
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

9.  Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound.

Authors:  H Ito; K Kamoi; K Yokoyama; K Yamada; T Nishimura
Journal:  Br J Radiol       Date:  2003-09       Impact factor: 3.039

10.  The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.

Authors:  Rojymon Jacob; Alexandra L Hanlon; Eric M Horwitz; Benjamin Movsas; Robert G Uzzo; Alan Pollack
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

View more
  10 in total

1.  Deformable MR-CBCT prostate registration using biomechanically constrained deep learning networks.

Authors:  Yabo Fu; Tonghe Wang; Yang Lei; Pretesh Patel; Ashesh B Jani; Walter J Curran; Tian Liu; Xiaofeng Yang
Journal:  Med Phys       Date:  2020-11-27       Impact factor: 4.071

2.  Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy.

Authors:  C Onal; S Sonmez; G Erbay; O C Guler; G Arslan
Journal:  Br J Radiol       Date:  2013-12-06       Impact factor: 3.039

3.  Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.

Authors:  Louise J Murray; John Lilley; Christopher M Thompson; Vivian Cosgrove; Josh Mason; Jonathan Sykes; Kevin Franks; David Sebag-Montefiore; Ann M Henry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-28       Impact factor: 7.038

4.  Whole prostate volume and shape changes with the use of an inflatable and flexible endorectal coil.

Authors:  Murat Osman; Haytham Shebel; Sandeep Sankineni; Marcelino L Bernardo; Dagane Daar; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey; Harsh K Agarwal
Journal:  Radiol Res Pract       Date:  2014-10-13

5.  Quantification of the margin required for treating intraprostatic lesions.

Authors:  Matthew T Studenski; Yanisley Valenciaga; Matthew C Abramowitz; Radka Stoyanova; Elizabeth Bossart; Nesrin Dogan; Alan Pollack
Journal:  J Appl Clin Med Phys       Date:  2016-05-08       Impact factor: 2.102

6.  The feasibility of a dose painting procedure to treat prostate cancer based on mpMR images and hierarchical clustering.

Authors:  Seyed Masoud Rezaeijo; Bijan Hashemi; Bahram Mofid; Mohsen Bakhshandeh; Arash Mahdavi; Mohammad Saber Hashemi
Journal:  Radiat Oncol       Date:  2021-09-20       Impact factor: 3.481

7.  A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.

Authors:  Tonghe Wang; Jun Zhou; Sibo Tian; Yinan Wang; Pretesh Patel; Ashesh B Jani; Katja M Langen; Walter J Curran; Tian Liu; Xiaofeng Yang
Journal:  Br J Radiol       Date:  2020-01-06       Impact factor: 3.039

8.  Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?

Authors:  Alison Tree; Caroline Jones; Aslam Sohaib; Vincent Khoo; Nicholas van As
Journal:  Radiat Oncol       Date:  2013-10-02       Impact factor: 3.481

9.  (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.

Authors:  Florian Sterzing; Clemens Kratochwil; Hannah Fiedler; Sonja Katayama; Gregor Habl; Klaus Kopka; Ali Afshar-Oromieh; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-25       Impact factor: 9.236

10.  Prostate cancer treated with reduced-volume intensity-modulated radiation therapy: Report on the 5-year outcome of a prospective series.

Authors:  Hua-Chun Luo; Zhi-Chao Fu; Hui-Hua Cheng; Yong Lei; Shao-Guang Liao; Jing Feng; Qin Yin; Qun-Hua Chen; Gui-Shan Lin; Jin-Feng Zhu; Jian-Feng Xu; Wang Dian
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.